Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: ARRAY-162-311: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas

 


ARRAY-162-311: The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas


Trial Focus

Female Reproductive Cancer

Objective

         This is a clinical trial of MEK162 that will be administered by mouth which is investigational or either liposomal doxorubicin, paclitaxel, or topotecan that will be administered by IV and are standard of care.

IRB Protocol #

13-2380

Trial Status

OPEN

Principle Investigator

KIAN BEHBAKHT

Sponsor

Array BioPharma, Inc

Contact

REBECCA KISSANE at (720)848-7202 or REBECCA.KISSANE@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last until study doctor determines it must be discontinued for safety reasons. A follow up period for remaining lifetime will consist of clinic visits every 12 weeks for tumor assessments. // Eligibility criteria include but are not limited to 18 years or older with cancer of the ovary, fallopian tube, or primary peritoneum.Eligibility criteria include but are not limited to 18 years or older with cancer of the ovary, fallopian tube, or primary peritoneum.